XT
ACAD icon

XTX Topco’s Acadia Pharmaceuticals ACAD Stock Holding History

XTX Topco’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-36,520
Closed -$593K – 2024
2024
Q2 		$593K Buy
+36,520
New +$589K 0.05% 577
2024
Q1 		– Sell
-12,961
Closed -$406K – 1776
2023
Q4 		$406K Sell
12,961
-22,962
-64% -$548K 0.09% 389
2023
Q3 		$749K Buy
+35,923
New +$976K 0.13% 194
2023
Q2 		– Sell
-31,261
Closed -$588K – 1359
2023
Q1 		$588K Buy
31,261
+6,686
+27% +$127K 0.12% 208
2022
Q4 		$391K Sell
24,575
-14,096
-36% -$220K 0.08% 419
2022
Q3 		$633K Buy
+38,671
New +$626K 0.16% 153
2021
Q3 		– Sell
-11,903
Closed -$290K – 655
2021
Q2 		$290K Buy
+11,903
New +$269K 0.1% 377

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

XTX Topco's ACAD Position: Q3 2024 in Review

XTX Topco sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 36,520 shares — an estimated $593K sold.

XTX Topco first reported a position in ACAD in Q2 2021 and held it in 7 quarters. The position peaked at $749K in Q3 2023. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • XTX Topco reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • XTX Topco sold 36,520 Acadia Pharmaceuticals shares in Q3 2024, an estimated $593K.
  • XTX Topco first reported a position in Acadia Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • XTX Topco's Acadia Pharmaceuticals position peaked at $749K in Q3 2023.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on XTX Topco's 13F filing for Q3 2024, filed 14 Nov 2024.